Fisher-Rosemount supplies advanced automation solution to Europe's AstraZeneca pharmaceuticals

AstraZeneca PLC looks to the DeltaV system as the automation solution for its new active pharmaceutical intermediates facilities in Gärtuna, Sweden and Dunkirque, France. The plants will manufacture active pharmaceutical ingredients for AstraZeneca’s world-leading gastrointestinal medicines.

The Gärtuna installation, the largest DeltaV installation to date in a pharmaceutical facility, is a two-phase operation. The first phase consists of two production areas with 9,000 connected I/O devices, 32 operator stations and 47 DeltaV controllers with integrated batch functionality. Phase two adds two more production areas of about the same size and scope. Fisher-Rosemount will also supply function specifications, application, training and testing. The plant will be validated and therefore the installation must be performed in accordance with cGMP (current Good Manufacturing Practice).

In order to wholly integrate the field devices with the DeltaV system, the latest technology is used in the automation solution. Fisher-Rosemount pressure/difference, pressure and radar gauge level transmitters will allow AstraZeneca to monitor the equipment for maximal access and better performance.

"We wanted to greatly reduce the time required to engineer, test and install the automation portion of this project," said Per Kronovall, project manager at AstraZeneca. "We expect this project to be completed in half the time of prior projects and look to time-saving technologies like DeltaV to help us accomplish our goals."